Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06215859 · ClinicalTrials.gov registry record · Phase 3

Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

A Phase 3 study of Pain and Postoperative Pain, sponsored by Viatris Specialty.

Completed
Registry status
Phase 3
Development phase
579
Enrollment target
18
Study locations

NCT06215859: Completed Phase 3 study of Pain and Postoperative Pain, sponsored by Viatris Specialty.

NCT06215859 is a Phase 3 study of Pain and Postoperative Pain that has completed, run by Viatris Specialty. The registered enrollment target is 579 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (91% higher). The trial reports 18 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06215859, a Phase 3 study of Pain and Postoperative Pain, has completed, sponsored by Viatris Specialty.

COMPLETED
Registry status
Phase 3
Development phase
579 participants
Enrollment target
18
Study locations

Study Summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

Primary Outcome

SPID based on a 0 to 10-point numeric rating scale with activity (NRS-A) for MR-107A-02 versus placebo.

Interventions

  • DRUG Placebo
  • DRUG Tramadol
  • DRUG MR-107A-02
  • PROCEDURE Herniorrhaphy

Study Locations (18)

Texas

  • Investigator site 212 - Bellaire
  • Investigator site 215 - Carrollton
  • Investigator site 204 - Houston
  • Investigator site 216 - McAllen
  • Investigator site 219 - San Antonio
  • Investigator site 203 - San Antonio
  • Investigator site 214 - San Antonio

California

  • Investigator site 202 - Anaheim
  • Investigator site 222 - Bakersfield
  • Investigator site 208 - Riverside

Florida

  • Investigator site 211 - Miami
  • Investigator site 206 - Tampa

Alabama

  • Investigator site 210 - Sheffield

Arizona

  • Investigator site 213 - Phoenix

Georgia

  • Investigator site 207 - Atlanta

Kansas

  • Investigator site 205 - Wichita

Utah

  • Investigator site 201 - Salt Lake City

Trial Details

FieldValue
Enrollment Target 579 participants
Start Date 2023-12-29
Est. Completion 2025-03-12
Phase Phase 3
Viatris Specialty

5 total trials

What the finished NCT06215859 record still lists

NCT06215859 is an interventional study that assigns participants to a tested intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap, above the 303-participant average among 374 other Pain trials with a reported enrollment target (91% higher).

The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT06215859 lists 18 locations in 9 states (Texas, California, Florida).

Frequently Asked Questions

What is clinical trial NCT06215859 about?

NCT06215859 is a clinical study titled "Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy". MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

What is the current status of trial NCT06215859?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 579 participants. The study started on 2023-12-29. Estimated completion is 2025-03-12.

What conditions does trial NCT06215859 study?

This clinical trial studies the following conditions: Pain, Postoperative Pain, Acute Pain.

What interventions are being tested in trial NCT06215859?

The interventions under investigation include: Placebo (DRUG), Tramadol (DRUG), MR-107A-02 (DRUG), Herniorrhaphy (PROCEDURE).

Who is sponsoring clinical trial NCT06215859?

This trial is sponsored by Viatris Specialty, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06215859 being conducted?

This trial has 18 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06215859's enrollment target sits among peer trials

579 26th of 374 higher than 349 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04575935 · 580 participants · Phase 3

    Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

  • NCT05143177 · 580 participants · Phase 2

    A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

  • NCT05696353 · 580 participants · Phase 3

    Teen Driving Translation Study (NIH)

  • NCT06578104 · 580 participants

    PULSED AF Post-Approval Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06215859, the US trial registry maintained by the National Library of Medicine. NCT06215859 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.